UTHR Share Price

Open 123.60 Change Price %
High 123.70 1 Day -0.97 -0.79
Low 121.00 1 Week 0.95 0.79
Close 121.74 1 Month -18.31 -13.07
Volume 674359 1 Year 4.29 3.65
52 Week High 169.89
52 Week Low 97.52
UTHR Important Levels
Resistance 2 124.24
Resistance 1 123.21
Pivot 122.15
Support 1 120.27
Support 2 119.24
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
AKRX 33.09 1.13%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
WRES 0.09 28.57%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 100.00%
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
CLNT 4.50 30.81%
CALI 3.45 29.21%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

United Therapeutics Corporation (NASDAQ: UTHR)

UTHR Technical Analysis 4
As on 25th Apr 2017 UTHR Share Price closed @ 121.74 and we RECOMMEND Sell for LONG-TERM with Stoploss of 129.49 & Strong Sell for SHORT-TERM with Stoploss of 142.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
UTHR Target for April
1st Target up-side 146.68
2nd Target up-side 154.6
3rd Target up-side 162.52
1st Target down-side 124.08
2nd Target down-side 116.16
3rd Target down-side 108.24
UTHR Other Details
Segment EQ
Market Capital 2447069440.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.unither.com
UTHR Address
UTHR
1040 Spring Street
Silver Spring, MD 20910
United States
Phone: 301-608-9292
Fax: 301-608-9291
Interactive Technical Analysis Chart United Therapeutics Corporation ( UTHR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on United Therapeutics Corporation
UTHR Business Profile
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Adcirca, Monoclonal Antibodies (MAbs), Glycobiology Antiviral Agents, Cell-Based Therapy, and Engineered Lungs and Lung Tissue for Transplantation. Prostacyclin analogues are stable synthetic forms of prostacyclin. Its product is Remodulin (treprostinil) Injection (Remodulin). PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in cells. Its PDE-5 inhibitor product is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of pulmonary arterial hypertension (PAH). MAbs act by targeting tumor-associated antigens on cancer cells to activate a patient's immune system against the cancer cells.